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ABSTRACT: 
 
Objective: The objective of this selective EBM review is to determine whether or not 
roxithromycin is effective in management of the signs and symptoms of rheumatoid arthritis.  
 
Study Design: Review of three primary studies in the English language published in 2006, 2009, 
and 2011. 
 
Data Sources: Randomized, controlled and double blind clinical trials testing the effectiveness 
roxithromycin in management of inflammation and signs and symptoms of rheumatoid arthritis 
were found using the PubMed and Ovid databases. 
 
Outcomes Measured: Improvement in the signs and symptoms of tenderness/inflammation using 
the American College of Rheumatology-20 (ACR-20) scoring approach, improvement of quality 
of life with the sinonasal outcome test-20 (SNOT-20) method, medication safety, and overall 
response to treatment. 
 
Results: The Ogrendik studies showed a significant number of patients met ACR 20 
improvement criteria with roxithromycin 300mg treatment at 6 months compared with those 
patients who received placebo.  One study showed significant reductions in pain and duration of 
morning stiffness, quality of life improvement, and reduction in disease activity as demonstrated 
by objective clinical measurements.  The Cervin et al study showed statistically significant 
improvements in sinonasal inflammation among patients who received roxithromycin 150mg, 
depicted by patient response scales.  Roxithromycin-treated patients in this study also showed 
significant improvements in SNOT-20 scoring after 12 weeks of treatment with the macrolide; 
however, improvements were not noted at the 6 week mark of treatment.   
 
Conclusions: Collectively, the three RCT’s evaluated depicted the effectiveness in management 
of signs and symptoms of rheumatoid arthritis.  Ogrendik studies indicate that this particular 
macrolide is effective in complaints that are most bothersome to RA patients, including morning 
stiffness and decreased quality of life.4,5  Also, the Cervin et al study proves the effectiveness of 
long-term use of roxithromycin in controlling inflammation.6  Further research is needed to 
assess the risk of bacterial resistance to roxithromycin with prolonged use, and whether or not 
there is a relationship between disease activity and antibodies to anaerobic bacteria among RA 
patients. 
 
Key words: inflammation, rheumatoid arthritis, roxithromycin 
 
 
 
 
 
 
 
  DiStanislao Effectiveness of Roxithromycin 
 
1 
 
Introduction: 
 
Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease, which primarily 
involves the synovitis of multiple joints. As an autoimmune disease, rheumatoid arthritis is 
considered a symmetric polyarthritis, with a tendency for the small joints of the hands and feet.1 
The distress of RA on the synovitis of joints in the human body typically results in pain and 
morning stiffness which lasts longer than thirty minutes.  In severe cases, there may be clinical 
presence of deformities including subcutaneous nodules and ulnar deviation of the wrist; in 
addition, there may be extra-articular findings on physical exam, such as: pericarditis, pleural 
effusion, interstitial lung disease, splenomegaly, and vasculitis.  The exact cause of RA is 
unknown.  However, there is known to be increased risk among people with HLA class II 
genotypes.  There are also known modifiable risk factors, including: smoking, use of oral 
contraceptives, use of HRT, women who breastfeed, and women with irregular menses/early 
menses.2  It is also of significant importance to note that high levels of antibodies to oral 
anaerobic bacteria have been found in both serum and synovial fluid of those with RA.5 
The disease process of rheumatoid arthritis can commence at any age; however, the peak 
onset of disease typically presents during the fourth or fifth decade for women and the sixth to 
eighth decades for men. While the prevalence of RA is 1%, it is seen more often in women, with 
a ratio of 3:1.1 
The exact total healthcare cost for RA could not be specified; however, 2009 statistics 
depict total hospital charges of $545 million (mean charge of $35,000 per person) related to 
treatment of the disease.2 Limited information is accessible regarding the total number of health 
care visits within the last several years; however, in 2007, there were 2.9 million ambulatory care 
visits in the United States among people with RA.  Most of these were physician office visits 
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(2.6 million) with 1.9 million visits to medical specialty offices.2   Statistics of 2009 indicate that 
there were 15,600 hospitalizations related to RA.2 
Treatment of rheumatoid arthritis typically involves both non-pharmacologic and 
pharmacologic regimens with efforts toward reduction of pain, inflammation, and deformities, as 
well as preservation of function.  Non-pharmacologic treatment includes OT/PT programs, 
systemic and articular rest, exercises which preserve joint motion and improve muscular 
strength, assistive devices and splints, as well as weight loss for patients over ideal body weight.  
Pharmacologic treatment typically begins with a synthetic disease-modifying antirheumatic drug 
(DMARD), with methotrexate being the initial treatment of choice.  The initial dose is typically 
7.5mg taken by mouth orally one time per week.  Improvement is typically not clinically 
apparent for 2-6 weeks.  Non-steroidal anti-inflammatory drugs (NSAIDS) are not effective 
when used as monotherapy, but may be used in conjunction with DMARDS.  Corticosteroid 
treatment, involving low dose prednisone, provides a rapid improvement in inflammation in 
patients suffering from RA.  They may be used temporarily as “bridge therapy” until DMARDS 
become effective; however, their side effects limit their role in long-term use.  Biologic 
DMARDS, including rituximab, TNF inhibitors, and abatacept, are effective in management of 
RA, however, are typically reserved for patients who do not respond to initial synthetic DMARD 
treatment.1  
One study (Cervin et al) mentions that substantial evidence has developed within the 
recent years suggesting that macrolide antibiotics may have an anti-inflammatory effect in 
addition to its antibiotic effect; however, their role in rheumatoid arthritis management has never 
been established.  For forthcoming discussion, roxithromycin is linked to the macrolide class.  
Macrolides are known to be both inhibitory and bactericidal.  Roxithromycin is available in 
  DiStanislao Effectiveness of Roxithromycin 
 
3 
 
Turkey and Australia (which accounted for the setting of the 3 RCTs utilized in this review) with 
a clinician’s prescription in the form of 150 and 300mg tablets; however availability and pricing 
of roxithromycin is unavailable to date in the United States. 7 
Objective: 
The objective of this selective EBM review is to determine whether or not roxithromycin 
is effective in management of the signs and symptoms of rheumatoid arthritis. 
Methods: 
 All studies utilize three, randomized, double-blind and controlled clinical trials.  
Participants consist of patients greater than 18 years of age with active signs and symptoms of 
inflammation.  Before entering the trials, all patients gave written informed consent.  All studies 
concentrated on the intervention roxithromycin, an oral antibiotic of the macrolide class, 
comparing its effects at varying doses to visually matched placebo.  No medications incorporated 
within the rheumatoid arthritis treatment regimen were to be given during the period of time in 
which the participants were studied.  
 There were two studies carried out by Ogrendik.  One involved the administration of 
roxithromycin 300 mg by mouth daily for 3 months or a visually matched placebo for 
comparison among 31 patients with active RA.4 The other also evaluated the comparison of 
roxithromycin 300mg by mouth daily versus a visually matched placebo to 100 patients; 
however, these interventions were provided for 6 months.5  Cervin et al involved patients with 
inflammation due to active rhinosinusitis and compared effects of roxithromycin 150mg by 
mouth daily for 3 months to visually matched placebo. 
 Data sources included studies found through PubMed and Ovid research databases 
throughout.  In order to encompass randomized controlled clinical trials on roxithromycin 
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effectiveness, key words during searches included: “roxithromycin”, “rheumatoid arthritis” and 
“inflammation”.  All articles were published in peer-reviewed journals in the English language.  
Articles were selected based on relevance to clinical topic of interest, dates in which they were 
published, and whether they represented patient-oriented evidence that matters.  To be 
considered as adequate studies to be reviewed, experimentation was required to involve 
randomized, controlled and double blind clinical trials published no earlier than 1996, as well as 
involve participants over the age of 18 years old.4,5,6  Exclusion criteria included: pregnant 
women, impaired hepatic/renal function, chronic/recurrent infections, history of adverse 
reactions to macrolides, recent dosages of steroids that were unstable or>7.5mg per day, recent 
intra-articular injections, diagnoses of RA for longer than 1 year previously, and immune 
deficiency.4,5,6 The summary of statistics reported include: p-value/confidence interval (CI), 
relative benefit increase (RBI), absolute benefit increase (ABI), absolute risk increase (ARI), 
relative risk reduction (RRR), numbers needed to treat (NNT), and numbers needed to harm 
(NNH). 
Table I: Demographics and characteristics of included studies for analysis of effectiveness of 
roxithromycin in management of inflammation and improvement of quality of life.  
Study Type # Pts Age 
(yrs) 
Inclusion Criteria Exclusion Criteria W/d Interventions 
Ogrendik 
(2009)4 
Double 
blind 
RCT 
100 18-70 Active RA: ≥10 swollen 
joints, ≥12 tender joints, 
and ≥1 of the following: 
ESR ≥28mm/h, CRP 
>2mg/dL, or morning 
stiffness for ≥45 min; 
inactive response to 1-4 
DMARDS or patients 
currently taking DMARDS 
with a washout period of 
≥1 month 
Pregnant women, 
impaired hepatic/renal 
function, 
chronic/recurrent 
infections, history of 
adverse reactions to 
macrolides 
9 Roxithromycin 
300mg for 6 
months 
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Ogrendik 
(2009)5 
Double 
blind 
RCT 
31 19-75  Recent dx (<1 year) of RA, 
RF positivity, and duration 
of disease >6 weeks and 
<1 year; ≥10 swollen 
joints, ≥12 tender joints, 
and ≥1 of the following: 
ESR ≥28mm/h, CRP 
>2mg/dL, or morning 
stiffness for ≥45 min 
Previous DMARD 
therapy, 
allergic/intolerant of 
roxithromycin, recent 
dosages of steroids 
that were unstable or 
>7.5mg/day, recent 
intra-articular 
injections, pregnant 
females, diagnosis of 
RA ≥1 year earlier, 
impaired hepatic/renal 
function, 
chronic/recurrent 
infections 
3 Roxithromycin 
300mg for 3 
months  
Cervin 
(2006)6 
Double 
blind 
RCT 
64 >18 y/o History consistent with the 
diagnosis of chronic 
rhinosinusitis as identified 
by the Rhinosinusitis Task 
Force 
History of cystic 
fibrosis, primary 
ciliary dyskinesia, 
immune deficiency, 
allergic fungal 
sinusitis, nasal 
polyposis, and 
impairment of 
liver/renal fxn; 
pregnant/breastfeeding 
women, known 
adverse reaction to 
macrolides 
3 Roxithromycin 
150mg daily for 3 
months 
Outcomes Measured 
 
 Two studies carried out by Ogrendik were utilized in the review of roxithromycin 
effectiveness among patients with RA.4,5  These studies focused on the percentage of patients 
who experienced a 20% improvement receiving roxithromycin 300mg or placebo.  The 20% 
improvement was measured by assessing ACR criteria (ACR 20 response) at 3 months in one of 
the studies.  This scoring system depicts a decrease of more than 20% in the number of tender 
joints and a 20% improvement in at least 3 of the following: global assessment of disease status, 
assessment of pain, assessment of physical function, physician’s global assessment of disease 
status, and CRP levels.4  The other study performed by Ogrendik assessed the same patient 
responses, however patients were given roxithromycin 300mg for 6 months.5  Both studies 
included follow-up assessments for 3 months following treatment or placebo administration.4,5 
Cervin et al is a randomized, controlled clinical trial which involved participants receiving either 
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roxithromycin 150mg or placebo daily for 3 months.  In order to assess quality of life, these 
patients completed subjective measurement of sinonasal outcome test-20 (SNOT-20) at the 
initiation of study, after 6 weeks of intervention, and then again after 12 weeks of treatment.  
This assessed patients’ quality of life following treatment with roxithromycin among patients 
with inflammation related to bacterial infections.6  
Results 
 Two of the studies (Ogrendik) which directly involved management of RA with 
roxithromycin 300mg among patients with active disease involved dichotomous data for 
interpretative results.4,5  Cervin et al, which involved assessment of roxithromycin in controlling 
inflammation and improving quality of life among patients with bacteria-induced rhinosinusitis 
involved continuous data which could not be converted to dichotomous values.6  All of the 
studies excluded patients under the age of eighteen and those with previous reactions to 
macrolide antibiotics.  Remarks on compliance behavior were not included in any of the three 
studies.4,5,6   
 The RCT conducted by Cervin et al assessed the subjective questionnaire called: 
Sinonasal Outcome Test-20 (SNOT-20), which is a validated, specific quality of life instrument 
in which patients with active nasal inflammation were asked 20 questions regarding 
improvement in quality of life.  The SNOT-20 depicted a significant improvement in quality of 
life for those treated with daily 150mg roxithromycin at 12 weeks (Table 2).  
Table 2: Mean change in baseline of SNOT-20 among patients receiving 300mg roxithromycin 
versus placebo.   
 Roxithromycin Group Placebo Group 
Pre-treatment 2.75±0.13 2.83± 0.12 
At 6 weeks 2.61±0.14 2.87±0.15 
At 12 weeks 2.34±0.19 2.88± 0.12 
At 24 weeks 2.49±0.18 2.84±0.15 
  DiStanislao Effectiveness of Roxithromycin 
 
7 
 
The results show a statistically significant decrease in SNOT-20 value at 12 weeks (p-
value<0.05) among patients receiving 300mg roxithromycin in comparison to placebo, indicating 
improvement in inflammation and quality of life.  There were no significant improvements noted 
in SNOT-20 scoring after 6 weeks of treatment or 3 months after the termination of treatment (p-
value>0.05).6 
Table 3 includes the confidence intervals calculated based on SNOT-20 scores of both 
treatment and placebo groups at 12 weeks post treatment.6 
Table 3: 95% CI calculated for SNOT-20 12 weeks post-treatment for experimental and placebo 
groups. 
Roxithromycin Placebo 
1.97-2.71 2.84-2.92 
 
Because there is no overlap among the calculated CIs, it can be inferred that there is a 
95% probability that the results of the two groups are truly different, and not different by chance.  
No significant differences were noted among SNOT-20 scores in terms of age, sex, and baseline 
values.  Nasal swabs were taken for microbiologic examination both before and after completion 
of treatment.  In the 29 patients treated with roxithromycin, there were 12 positive cultures at the 
begininning of treatment; S. aureus n=4, H. Flu n=1, P. aeruginosa n=3, S. pneumonia n=4. 
Following treatment of these patients, there were 9 positive cultures; S. aureus n=5, H. Flu n=2, 
P. aeruginosa n=2, S. pneumonia n=2.6  
 The two RCTs conducted by Ogrendik compared oral roxithromycin 300mg with placebo 
among adult patients of 18 years or older in a primary outpatient clinic who are managing 
rheumatoid arthritis.4,5  One of the studies treated patients for 3 months and the other for 6 
months.4,5 The study that assessed participants for 3 months depicted more patients who received 
roxithromycin 300mg experienced ACR-20 responses at 3 months compared to patients who 
received placebo (Table 4).4   
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Table 4: Analysis of RBI, ABI, and NNT of RCTs conducted by Ogrendik.4,5 
 Relative benefit 
increase (RBI) 
Absolute benefit 
increase (ABI) 
Numbers needed to 
treat (NNT) 
Ogrendik 3mo. RCT4 275% 55% 2 
Ogrendik 6mo. RCT5 76% 26% 4 
 The NNT for the 3-month RCT indicates that 2 patients would need to be treated with 
roxithromycin 300mg in order to increase the likelihood of reduction of joint tenderness and 
inflammation among one patient.4 Likewise, the NNT that represents the 6-month RCT specifies 
that 4 patients would need to be treated in order to increase the likelihood of ACR-20 among one 
patient with rheumatoid arthritis.5   
Safety 
 Few participants among the three RCTs experienced adverse events throughout the 
conveyance of the studies.  Roxithromycin was well tolerated among patients and no deaths were 
reported.  Of those that did experience adverse effects throughout the trials, gastrointestinal 
complaints (including nausea, vomiting, and abdominal pain) were most frequent between all 
studies.4,5,6  Tables 4 and 5 are indicative of the analyses of numbers needed to harm among both 
placebo and groups receiving 300mg roxithromycin in the RCTs conducted by Ogrendik.4,5,6 
Table 5: Analysis of adverse events among placebo and experimental groups of Ogrendik’s 3-
month RCT.4 
Side Effect Relative Risk 
Increase (RRI) 
Absolute Risk 
Increase (ARI) 
Number Needed to 
Harm (NNH) 
GI pain 86.6% 5.8% 17 
Nausea 86.6% 5.8% 17 
Vomiting 0 0 0 
Table 6: Analysis of adverse events among placebo and experimental groups of Ogrendik’s 6-
month RCT.5 
Side Effect Relative Risk 
Increase (RRI) 
Absolute Risk 
Increase (ARI) 
Number Needed to 
Harm (NNH) 
GI pain 250% 10% 10 
Nausea 50% 40% 2.5 
Vomiting 50% 20% 50 
 As seen above in Tables 4 and 5, number needed to harm (NNH) was calculated based on 
most frequent adverse events.  Of this subset, for example, the NNH for GI pain in Ogrendik’s 3-
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month RCT was 17, meaning that for every 17 patients taking roxithromycin, 1 additional would 
be experiencing GI pain in comparison to those not taking the drug.4  The remaining NNH from 
Ogrendik’s studies are depicted above. There were a total of five patients who withdrew from the 
Cervin et al study.  Two of the three that withdrew from the placebo group did so due to a rash 
and abdominal pain.  From the two subjects that withdrew from the roxithromycin group, one 
revoked due nausea and vomiting.6 
Discussion: 
 The two RCTs conducted by Ogrendik demonstrated the effectiveness of roxithromycin, 
of the macrolide class, among adults patients with signs and symptoms of inflammation related 
to active rheumatoid arthritis.4,5  However, also relating to the recent question as to whether or 
not roxithromycin has both anti-inflammatory and antibiotic effects, Cervin et al involved the 
treatment of patients with roxithromycin who suffered signs and symptoms of chronic 
rhinosinustis due to bacterial infections.6    
When available, roxithromycin may be used for: pharyngitis, impetigo, bronchitis, 
tonsillitis, pneumonia, non-gonococcal urethritis, and skin and soft tissue infections.  There has 
been no evidence supporting addiction to roxithromycin antibiotic.  Roxithromycin is 
contraindicated for any patient who has an allergic reaction to any of the other drugs included 
within the macrolide class, such as: clarithromycin, erythromycin, or azithromycin.7 Bacteria that 
have depicted full clinical susceptibility to roxithromycin include: Strep. agalactiae, Strep. 
Pneumonia, N. meningitides, L. monocytogenes, anaerobic Myco. pneumoniae, C. trachomatis, 
Ureaplasma urealyticum, Legionella pneumophila, Helicobacter, Gardnerella vaginalis, 
Bordetella pertussis, Moraxella catarrhalis (Branhamella Catarrhalis), and Haemophilus 
ducreyi.9  
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One of the older members of macrolide class, erythromycin, has advanced in terms of 
treatment coverage over the last few years; however, studies have also shown limitations to its 
use. Barriers known to treatment with this particular intervention include several daily drug 
administrations and the gastrointestinal-related side effects, which abate compliance with these 
medications.  Studies reviewed in 1992 looked at the “newer” macrolides, including 
azithromycin, clarithromycin, dirithromycin, and roxithromycin and their advantages over their 
precedent erythromycin.  Specifically speaking, roxithromycin is widely distributed throughout 
various tissues and regions of the body, with a half-life of approximately 12 hours.  These studies 
indicated the benefits of the newer macrolides in their superior activity against certain bacterial 
organisms, increased bioavailability due to acid resistance, and improvement in the incidence of 
adverse gastrointestinal effects.  However, these adverse reactions do still exist, even among the 
most recent additions of this class.  Gastrointestinal side effects are thought to be related to 
motilin, a naturally occurring bodily hormone that promotes gastric motility.8  
Limitations of the studies were noted among the 3 RCTs.  Small patient population sizes 
were found in the 3-month Ogrendik and Cervin et al studies.  Because the Ogrendik RCTs were 
carried out in a similar fashion, some limitations overlapped among the two studies and include: 
the risk of bacterial resistance to roxithromycin with prolonged use not being evaluated, adverse 
events based solely on patient self-report, and no measurement of bacterial antibody 
concentrations.  In addition, the 3-month trial exclusion criteria involved patients who did not 
previously receive DMARD therapy, which may have led to selection of patients with less severe 
RA.4,5,6  More specific limitations were also found with Cervin et al.  The longevity of the 
treatment effect and optimal duration of treatment still remain unknown, and benefits of 
treatment should be weighed in comparison to risks of noted side effects. Although improvement 
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of rhinosinusitis was noted, no patients admitted to “complete improvement” at the end of the 
study.  In addition, despite evidence of reduction of inflammation among anaerobes P. 
aeruginosa & falcutative anaerobe H. influenzae induced infections, reduction in anaerobic 
bacteria that more specifically match those found in joints of RA patients would have provided 
more significant and direct evidence.6 
Conclusions: 
 In conclusion, studies that look directly at the effectiveness of management of active RA 
with roxithromycin do show significant improvement in signs and symptoms. However, the 
evidence of whether or not macrolides are effective in managing the signs and symptoms of 
rheumatoid arthritis are conflicting due to limitations of studies.  It is unknown if and when 
future studies will take place in the United States due to unavailability of roxithromycin.  
However, for further studies that do take place, several recommendations would be made to 
eliminate flaws and limitations.  For one, larger studies are warranted.  In addition, investigation 
of the relationship between disease activity and serum/joint antibodies to bacteria may be more 
interpretive of results.  Measurement of specific oral or nasal flora may help in identification of 
subgroups that would be best targeted for treatment.  Studies may also be more significant if 
inclusion criteria consisted of only patients with RA who have previously failed with DMARD 
therapy.   
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